/NRXP
NRXP Stock - NRx Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$2.37+8.72%
+$0.19 (+8.72%) • Dec 19
30
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.21
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).19
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.43
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-15.6%upside
Target: $2.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NRXP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.35 – $2.39
TARGET (TP)$2.00
STOP LOSS$2.18
RISK/REWARD1:-1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.92
52W High$6.01
52W Low$1.40
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-5,000 | $-5,000 | $-4,000 | $-2,000 | $-2,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-19,704,000 | $-27,587,000 | $-44,335,000 | $-95,201,000 | $-22,061,000 |
| Net Income | $-25,126,000 | $-30,150,000 | $-39,754,000 | $-93,063,000 | $-51,777,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.39 | $-3.98 | $-0.60 | $-7.44 | $-1.51 |
Company Overview
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$29
Average Target
↑ 1123.6% Upside
Now
$18
Low
$29
Average
$40
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 8th 2025 | H.C. Wainwright | Initiation | Buy | $40 |
| April 2nd 2025 | BTIG Research | Initiation | Buy | $18 |
Earnings History & Surprises
NRXPBeat Rate
46%
Last 13 quarters
Avg Surprise
-2.9%
EPS vs Estimate
Beats / Misses
6/6
1 met exactly
Latest EPS
$-0.18
Q4 2025
EPS Surprise History
Q4 23
+36.4%
$-0.70vs$-1.10
Q1 24
+28.6%
$-0.50vs$-0.70
Q2 24
-34.5%
$-0.74vs$-0.55
Q3 24
+7.4%
$-0.75vs$-0.81
Q4 24
+81.5%
$-0.15vs$-0.81
Q1 25
-50.0%
$-0.30vs$-0.20
Q2 25
-13.3%
$-0.34vs$-0.30
Q4 25
-63.6%
$-0.18vs$-0.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 13, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.11 | $-0.18 | -63.6% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.30 | $-0.34 | -13.3% | ✗ MISS |
Q1 2025 | Mar 14, 2025 | $-0.20 | $-0.30 | -50.0% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.81 | $-0.15 | +81.5% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.81 | $-0.75 | +7.4% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.55 | $-0.74 | -34.5% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-0.70 | $-0.50 | +28.6% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-1.10 | $-0.70 | +36.4% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-1.40 | $-1.20 | +14.3% | ✓ BEAT |
Q2 2023 | May 16, 2023 | $-1.50 | $-1.30 | +13.3% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-1.40 | $-1.50 | -7.1% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-1.40 | $-1.40 | 0.0% | = MET |
Q3 2022 | Aug 15, 2022 | $-1.00 | $-1.50 | -50.0% | ✗ MISS |
Q2 2022 | May 16, 2022 | — | $-2.50 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.90 | — | — |
Q4 2021 | Nov 16, 2021 | — | $-3.90 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-65.10 | — | — |
Q2 2021 | May 20, 2021 | — | $-0.71 | — | — |
Latest News
NRx Pharmaceuticals Repays Remaining $5.4M Balance Sheet Debt To Anson Funds Through Equity Conversion Of Common Stock
➖ NeutralBenzinga•Dec 18, 2025, 12:09 PM
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $40 Price Target
📈 PositiveBenzinga•Dec 16, 2025, 12:09 PM
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target
📈 PositiveBenzinga•Dec 3, 2025, 08:26 PM
NRx Pharma Pursues "One-Day" Depression Treatment That Could Be Twice as Effective as Standard Pills
📈 PositiveBenzinga•Dec 3, 2025, 12:13 PM
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $25 Price Target
📈 PositiveBenzinga•Dec 3, 2025, 10:45 AM
NRXP stock has given up its prior gain. NRx Pharmaceuticals shares were trading higher after the company announced the FDA received the Abbreviated New Drug Application for KETAFREE.
➖ NeutralBenzinga•Dec 2, 2025, 05:58 PM
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target
📈 PositiveBenzinga•Dec 2, 2025, 03:20 PM
NRx Pharmaceuticals shares are trading higher after the company announced the FDA received the Abbreviated New Drug Application for KETAFREE.
📈 PositiveBenzinga•Dec 2, 2025, 01:50 PM
NRx Pharmaceuticals Announces FDA Has Received Co.'s Abbreviated New Drug Application For KETAFREE
📈 PositiveBenzinga•Dec 2, 2025, 01:33 PM
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target
📈 PositiveBenzinga•Nov 17, 2025, 01:33 PM
As Of September 30, 2025, NRx Pharmaceuticals Had Approximately $7.1M In Cash And Cash Equivalents, Which Is Expected To Support Operations At Least Through Q2 Of 2026
➖ NeutralBenzinga•Nov 17, 2025, 01:07 PM
NRX Pharmaceuticals Q3 EPS $(0.27) May Not Be Comparable To $0.18 Estimate, Sales $242.000K May Not Be Comparable To $15.000M Estimate
➖ NeutralBenzinga•Nov 17, 2025, 01:06 PM
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target
📈 PositiveBenzinga•Nov 10, 2025, 06:21 PM
HOPE Therapeutics Launches First-in-Florida Deployment Of Ampa ONE-D Protocol, Achieving Single-Day Remission Rates Up To 72% In Treatment-Resistant Depression
📈 PositiveBenzinga•Nov 10, 2025, 01:14 PM
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $47
📈 PositiveBenzinga•Oct 30, 2025, 11:16 AM
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target
📈 PositiveBenzinga•Oct 21, 2025, 11:11 AM
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $40 Price Target
📈 PositiveBenzinga•Oct 16, 2025, 10:42 AM
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $40 Price Target
📈 PositiveBenzinga•Oct 1, 2025, 10:51 AM
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target
📈 PositiveBenzinga•Sep 29, 2025, 01:50 PM
NRx Pharmaceuticals Re-Files Its Abbreviated New Drug Application With FDA For KETAFREE
➖ NeutralBenzinga•Sep 29, 2025, 12:22 PM
Frequently Asked Questions about NRXP
What is NRXP's current stock price?
NRx Pharmaceuticals, Inc. (NRXP) is currently trading at $2.37 per share. The stock has moved +8.72% today.
What is the analyst price target for NRXP?
The average analyst price target for NRXP is $2.00, based on 1 analyst.
What sector is NRx Pharmaceuticals, Inc. in?
NRx Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NRXP's market cap?
NRx Pharmaceuticals, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does NRXP pay dividends?
No, NRx Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCOEP
Coeptis Therapeutics, Inc.
$14.66
Mkt Cap: $0.1B
CUE
Cue Biopharma, Inc.
$0.27
Mkt Cap: $0.0B
EQ
Equillium, Inc.
$1.15
Mkt Cap: $0.0B
HOWL
Werewolf Therapeutics, Inc.
$0.69
Mkt Cap: $0.0B
IOBT
IO Biotech, Inc.
$0.66
Mkt Cap: $0.0B
IPSC
Century Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
KPTI
Karyopharm Therapeutics Inc.
$6.94
Mkt Cap: $0.1B
OTLK
Outlook Therapeutics, Inc.
$2.01
Mkt Cap: $0.1B
SNTI
Senti Biosciences, Inc.
$1.20
Mkt Cap: $0.0B
SPRB
Spruce Biosciences, Inc.
$78.74
Mkt Cap: $0.0B
Explore stocks similar to NRXP for comparison